Efficacy of VRD-lite regimen in the treatment of multiple myeloma and its effect on the expression of serum miR-223-3p,miR-140-5p
Sun Yongle
Chen Zhe
Hao Jie
Jiang Min
Yan Hanying
Zhang Ling
Abstract：Objective To investigate the therapeutic efficacy of bortezomib+dexamethasone+lenalidomide(VRD-lite)regimen on multiple myeloma and its effect on the expression of serum miR-223-3p and miR-140-5p.Methods Ninety patients with multiple myeloma admitted to the Department of Hematology of the First Hospital Affiliated to Hebei North Col-lege from June 2020 to June 2023 were selected as the study subjects,and were divided into the control group and the study group by the envelope method,each with 45 cases.The control group was treated with bortezomib combined with dexametha-sone,and the study group was treated with lenalidomide based on the control group therapy.We compared the effect of the 2 groups after 3 months of treatment,serum miR-223-3p,miR-140-5p expression,myeloma examination,inflammatory response,renal function indexes,and patients' survival quality.Results The total effective rate of treatment in the study group was 86.67％,which was higher than 68.89％in the control group(x2/P=4.114/0.043);after the treatment,the expression lev-els of serum miR-223-3p and miR-140-5p in both groups were elevated,and the study group was higher than the control group.were elevated,and the study group was higher than the control group(t/P=4.590/＜0.001,4.257/＜0.001).Serum M protein,β2 microglobulin,and proportion of myeloma cells levels were decreased in the 2 groups after treatment and were lower in the study group than in the control group(t/P=11.783/＜0.001,37.964/＜0.001,11.493/＜0.001).IL-6,IL-17,TGF-β,SCr,BUN,24-h urine protein levels and PS scores were lower in both groups after treatment compared with before treatment,and lower in the study group(t/P=21.920/＜0.001,69.118/＜0.001,5.066/＜0.001,16.822/＜0.001,8.183/＜0.001,3.472/0.001,4.525/＜0.001),KPS and QOL scores were elevated and higher in the study group than in the control group(t/P=14.156/＜0.001,15.250/＜0.001).Conclusion VRD-lite regimen has significant efficacy in the treatment of multiple myeloma,which can significantly improve the renal function,inflammatory response status and quality of life,and positively affect the expres-sion of serum miR-223-3p and miR-140-5p.
Keywords：Multiple myelomaBortezomib+dexamethasone+lenalidomide regimenmiR-223-3pmiR-140-5pTherapeutic effect
Publication Date：2025-07-18
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 826-831 )